Single-dose ¹⁷⁷Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial.

ABSTRACT:

Background

Checkpoint inhibitors have been shown to have limited activity in patients with metastatic castration-resistant prostate cancer. We aimed to determine whether a single dose of lutetium-177 [¹⁷⁷Lu]-prostate-specific membrane antigen (PSMA)-617 (¹⁷⁷Lu-PSMA-617) followed by maintenance pembrolizumab was safe and could induce durable clinical benefit.

Methods

We did an open-label, dose-expansion, phase 1 study at the University of California, San Francisco (San Fransisco, CA, USA). Eligible patients were men aged 18 years or older with progressive metastatic castration-resistant prostate cancer who had an Eastern Cooperative Oncology Group performance status of 0 or 1, had progression on one or more androgen signalling inhibitors, and at least th

SUBMITTER: Aggarwal R 

PROVIDER: S-EPMC10667020 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature